Nasdaq:WSB the parent company of Washington Savings Bank F

(Nasdaq:WSB), the parent company of Washington Savings Bank, F.S.B., (the "Bank")today announced results of operations for its first quarter ending March 31,2009.WSB Holdings reports net loss of $2.1 million or $(0.27) per basic anddiluted share for the three months ended March 31, 2009. BOWIE, Md., April 22 /PRNewswire-FirstCall/ -- WSB Holdings, Inc. For additional information about Metabolexand its development pipeline, visit , Inc.Donald Hill of Metabolex, Inc., +1-510-293-8800, . has the exclusive right to develop andcommercialize MBX-102/JNJ 39659100. The company has four clinical-stage compounds:MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044,which has completed a Phase 2a trial; MBX-8025, which has completed a Phase 2trial in patients with dyslipidemia; and MBX-2982, which has completed a Phase1 trial Ortho-McNeil, Inc.

Metabolex has drawnon its deep understanding of diabetes to create a large database of genesinvolved in diabetes and to build a rich pipeline of product candidates anddrug discovery targets. Van Wart added, "I would like to thank Rob for his manyvaluable contributions to Metabolex during his Board tenure."About MetabolexMetabolex is a privately-held biopharmaceutical company focused on thediscovery and development of proprietary new medicines for the treatment ofmetabolic diseases, with an emphasis on type 2 diabetes. vonEmster's appointment follows the resignation of Rob Chess from the Board ofDirectors.Dr. "We look forward to his input and expertise asthe company continues to build upon its recent clinical successes." Mr. von Emster brings to the Board the perspective of a seasoned private andpublic company investor," said Harold Van Wart, Ph.D., president and chiefexecutive officer of Metabolex.

degree from the University of California at SantaBarbara."Mr. von Emster is aChartered Financial Analyst (CFA), a member of the Association for InvestmentManagement and Research and of the Security Analysts of San Francisco Mr vonEmster received his B.S. von Emster iscurrently a member of the board of directors at Somaxon Pharmaceuticals, Inc.,and Facet Biotech, both public biotechnology companies.Mr. von Emster was with the Franklin Templeton Group,most recently as a Vice President and Portfolio Manager.Mr. von Emster was Managing Director of MPMBioEquities and a Portfolio Manager for the MPM BioEquities Fund.From July1989 to November 2000, Mr. von Emster currently serves as a Managing Director of venBio.FromNovember 2000 to March 2009, Mr.